A synthetic biology research engine in South San Francisco. ML-driven sequence optimization, proprietary safety and targeting tools, and producer cell line engineering — all in service of getting your therapy to the clinic faster.
Our Genetic Design is where therapeutic candidates are conceived, optimized, and de-risked before they ever hit a bioreactor. We combine synthetic biology expertise, bioinformatics, and proprietary building blocks into a design environment built for the clinic.
Gene-of-interest, promoter, regulatory element, and payload architecture optimized across CAR/TCR-T, NK, Treg, and in-vivo gene therapy modalities.
Parallel evaluation of construct variants in primary and therapeutically relevant cell types — narrowing thousands of candidates to the few worth bringing into the clinic.
Bioinformatics analysis, protein and promoter library design, and AI-based protein design — sharpening which constructs make it into wet-lab screens.
Promoters designed for in-vivo cell therapy programs — driving expression in the target cell population, silent everywhere else.
Gene-expression switches optimized by directed evolution to respond to therapeutically relevant concentrations of FDA-approved small molecules with excellent pharmacological properties — giving clinicians dosable control of the engineered cell.
Selective elimination of engineered cells when needed — our system is optimized for rapid cell death, giving programs a robust safety lever that engages quickly when it's called for.
The full set of capabilities that make up our integrated CDMO platform.
End-to-end autologous & allogeneic workflows — CAR-T, NK, Treg, in-vivo GT.
Adherent & suspension lentivirus — 2 L to 200 L GMP. Targeting and control built in.
Engineering, Master, and Working cell bank generation. Adherent & suspension.
Knowledge transfer as a discipline. Development-to-GMP in ~7 months.
Dedicated PMO, transparent Gantts, real-time data exchange. One accountable team.
